| Previous Close | 34.07 |
| Open | 33.99 |
| Day High | 34.42 |
| Day Low | 31.44 |
| 52-Week High | 38.04 |
| 52-Week Low | 10.62 |
| Volume | 414,070 |
| Average Volume | 422,301 |
| Market Cap | 1.42B |
| PE | -29.22 |
| EPS | -1.08 |
| Moving Average 50 Days | 31.44 |
| Moving Average 200 Days | 26.55 |
| Change | -2.51 |
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
GlobeNewswire Inc.
Mar 01, 2026 2:45 PM GMT
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable
Septerna to Present at TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026,